Cargando…
Bendamustine: Safety and Efficacy in the Management of Indolent Non-Hodgkins Lymphoma
Bendamustine (Treanda, Ribomustin) was recently approved by the US Food and Drug Administration (FDA) for treatment of patients with rituximab refractory indolent lymphoma and is expected to turn into a frontline therapy option for indolent lymphoma. This compound with amphoteric properties was desi...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Libertas Academica
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3117628/ https://www.ncbi.nlm.nih.gov/pubmed/21695099 http://dx.doi.org/10.4137/CMO.S6085 |
_version_ | 1782206348122914816 |
---|---|
author | Tageja, Nishant |
author_facet | Tageja, Nishant |
author_sort | Tageja, Nishant |
collection | PubMed |
description | Bendamustine (Treanda, Ribomustin) was recently approved by the US Food and Drug Administration (FDA) for treatment of patients with rituximab refractory indolent lymphoma and is expected to turn into a frontline therapy option for indolent lymphoma. This compound with amphoteric properties was designed in the former Germany Democratic Republic in 1960s and re-discovered in 1990s with multiple successive well-designed studies. Bendamustine possesses a unique mechanism of action with potential antimetabolite properties, and only partial cross-resistance with other alkylators. Used in combination with rituximab in vitro, bendamustine shows synergistic effects against various leukemia and lymphoma cell lines. In clinical studies, bendamustine plus rituximab is highly effective in patients with relapsed-refractory indolent lymphoma, inducing remissions in 90% or more and a median progression-free survival of 23–24 months. The optimal dosing and schedule of bendamustine administration is largely undecided and varies among studies. Results of ongoing trials and dose-finding studies will help to further help ascertain the optimal place of bendamustine in the management of indolent NHL. |
format | Online Article Text |
id | pubmed-3117628 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2011 |
publisher | Libertas Academica |
record_format | MEDLINE/PubMed |
spelling | pubmed-31176282011-06-21 Bendamustine: Safety and Efficacy in the Management of Indolent Non-Hodgkins Lymphoma Tageja, Nishant Clin Med Insights Oncol Review Bendamustine (Treanda, Ribomustin) was recently approved by the US Food and Drug Administration (FDA) for treatment of patients with rituximab refractory indolent lymphoma and is expected to turn into a frontline therapy option for indolent lymphoma. This compound with amphoteric properties was designed in the former Germany Democratic Republic in 1960s and re-discovered in 1990s with multiple successive well-designed studies. Bendamustine possesses a unique mechanism of action with potential antimetabolite properties, and only partial cross-resistance with other alkylators. Used in combination with rituximab in vitro, bendamustine shows synergistic effects against various leukemia and lymphoma cell lines. In clinical studies, bendamustine plus rituximab is highly effective in patients with relapsed-refractory indolent lymphoma, inducing remissions in 90% or more and a median progression-free survival of 23–24 months. The optimal dosing and schedule of bendamustine administration is largely undecided and varies among studies. Results of ongoing trials and dose-finding studies will help to further help ascertain the optimal place of bendamustine in the management of indolent NHL. Libertas Academica 2011-05-18 /pmc/articles/PMC3117628/ /pubmed/21695099 http://dx.doi.org/10.4137/CMO.S6085 Text en © the author(s), publisher and licensee Libertas Academica Ltd. This is an open access article. Unrestricted non-commercial use is permitted provided the original work is properly cited. |
spellingShingle | Review Tageja, Nishant Bendamustine: Safety and Efficacy in the Management of Indolent Non-Hodgkins Lymphoma |
title | Bendamustine: Safety and Efficacy in the Management of Indolent Non-Hodgkins Lymphoma |
title_full | Bendamustine: Safety and Efficacy in the Management of Indolent Non-Hodgkins Lymphoma |
title_fullStr | Bendamustine: Safety and Efficacy in the Management of Indolent Non-Hodgkins Lymphoma |
title_full_unstemmed | Bendamustine: Safety and Efficacy in the Management of Indolent Non-Hodgkins Lymphoma |
title_short | Bendamustine: Safety and Efficacy in the Management of Indolent Non-Hodgkins Lymphoma |
title_sort | bendamustine: safety and efficacy in the management of indolent non-hodgkins lymphoma |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3117628/ https://www.ncbi.nlm.nih.gov/pubmed/21695099 http://dx.doi.org/10.4137/CMO.S6085 |
work_keys_str_mv | AT tagejanishant bendamustinesafetyandefficacyinthemanagementofindolentnonhodgkinslymphoma |